OraLiva
PrivateLast Round
Seed
Sep 22, 2025
Total Funding Raised
$5.84M
Company Overview
OraLiva operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Seed round in September 2025.
OraLiva is a diagnostic equipment company that has developed an AI-powered cytology platform for the early detection of oral cancer.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Usage-Based SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
OraLiva Comparables
Compare OraLiva with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OrisDX | 91% | |
| Vigilant Biosciences | 85% | |
| Forward Science | 79% |
For institutional investors. Book with your work email.
OraLiva Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 22, 2025 | ||||
| Grant | Aug 15, 2025 | ||||
| Grant | Jul 10, 2025 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
OraLiva Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant, Seed |
| NIH RADx | Grant |
| RTP Angel Fund | Seed |
| New York University | Seed |
| National Institute of Dental and Craniofacial Research | Grant, Seed |
| NYU Innovation Venture Fund | Seed |
| National Science Foundation | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 22, 2025
Launched a new oral cancer test.
- Sep 22, 2025
Launching AI-powered cytology platform for early oral cancer diagnosis.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 30, 2026
The Digital Health Hub Foundation recognizes OraLiva, Inc. as a Quarterfinalist in the 2026 Digital Health & AI Awards in Sep '26, after which the company advances to the Finalist round.
- recognized_asOct 30, 2026
The Digital Health & AI Awards name OraLiva, Inc. a Finalist in the Rising Star track’s Cancer, Screening & Early Detection category on Oct 12th '26 in North Carolina, after the company advances from the Quarterfinalist round.
For institutional investors. Book with your work email.
OraLiva Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about OraLiva's valuation, stock price, and market status.
Is OraLiva a public or private company?
OraLiva is a private company.
What is the current stock price of OraLiva?
OraLiva is a private company, so its shares have no public market price. Caplight tracks OraLiva's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is OraLiva worth (valuation)?
Valuation information for OraLiva is not publicly available.
Can I buy OraLiva stock?
OraLiva shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was OraLiva's last funding round?
OraLiva's most recent funding round was Seed on September 22, 2025.
Who are the main investors in OraLiva?
Key investors in OraLiva include National Cancer Institute, NIH RADx, RTP Angel Fund, New York University, National Institute of Dental and Craniofacial Research.
Will OraLiva IPO soon?
No public IPO plans have been announced for OraLiva.
How can I track OraLiva secondary market activity?
Caplight tracks bids, offers, and trades in OraLiva's shares on secondary markets.